Notably, PRNP showed the strongest positive correlation with RRM1 (Pearson’s R = 0.37, p < 0.05), supporting its prioritization as a potential therapeutic target for overcoming gemcitabine resistance in pancreatic cancer (Figure 2E). This evidence concerns the gene RRM1 and pancreatic neoplasm.